拉米夫定联合灵芝胶囊治疗慢性乙型肝炎30例临床观察  

Treatment of Chronic Hepatitis B by Lamivudine Combined with Lingzhi Capsule:A Clinical Observation of 30 Cases

作　　者：陈培琼[1] 池晓玲[1] 田广俊[1] 李金菊[1] 

机构地区：[1]广州中医药大学第二临床医学院,广东广州510120

出　　处：《新中医》2007年第3期78-79,共2页New Chinese Medicine

摘　　要：目的：观察灵芝胶囊联合拉米夫定治疗慢性乙型肝炎的疗效。方法：将60例患者随机分为治疗组与对照组各30例。治疗组给予口服用灵芝胶囊、联合拉米夫定；对照组口服拉米夫定。疗程均为1年。结果：治疗组在促进HBV—DNA转阴、HBeAg阴转及HBeAg/HBeAb血清转换方面,优于对照组(P＜0．05)；治疗组能够较早使ALT恢复正常,并且最终复常率明显优于对照组,2组比较,差异有显著性意义(P＜0．05)；YMDD变异治疗组有1例,对照组有6例,2组比较,差异有显著性意义(P＜0．05),提示治疗组联合治疗产生YMDD变异少于对照组。结论：灵芝胶囊与拉米夫定联合应用治疗慢性乙型肝炎有明显的协同作用,可显著改善肝功能、快速抑制HBV—DNA的复制、促使HBeAg的阴转和血清转换,短期疗效优于单用拉米夫定。Objective:To observe the curative effect of lamivudiae combined with Lingzhi capsule(LC,灵芝胶囊)for chronic hepatitis B(CHB).Methods:60 cases of CHB were allocated to 2 groups(each group 30 cases)randomly.The treatment group was treated by oral use of LC combined with lamisudine and coronal group by lamivudine alone.One year constituted the course of treatment.Results:In treatment group,the promotion of turniag negative HBV-DNA,HBeAg and transfer of H BeAg/Anti-HBe were superior than that of control group(P＜0.05);the recovery rate of ALT was earlier in treatment group than that of control group(P＜0.05);the variation of YMDD was one case and 6 cases in treatment group and control group respectively(P＜0.05).it is indi- cated that the variation of YMDD of treatment group was less than that of control group.Gonclusion:LC combined with lamivudine showed marked synergistic action for CHB,markedly improve liver function,inhibit the replication of HBV-DNA rapidly,promote the turning negative of HBeAg and the transfer of serum,and the short-term curative effect is superior than that of lamivudine,group.

关 键 词：慢性乙型肝炎 拉米夫定 灵芝胶囊 乙型肝炎病毒 

分 类 号：R512.62[医药卫生—内科学]